Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAI-GO for CD33+ AML
NCT00909168Phase 3Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Udine
- Start
- Mar 2008
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Azienda Ospedaliero-Universitaria di Udine. Started Mar 2008; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00909168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00909168.